Ironwood offers upbeat PhIII data details on linaclotide

Ironwood and Forest Labs took the stage at the Digestive Disease Week conference to spell out their promising Phase III data on linaclotide, Ironwood's closely-watched treatment for irritable bowel syndrome with constipation. The therapy achieved statistically significant results for the primary as well as all secondary endpoints. "The results of these trials suggest that linaclotide may provide an attractive option for millions of patients suffering from chronic constipation," said investigator Anthony Lembo, M.D. Ironwood release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.